PAVM vs ISRG vs SYK vs NVCR vs MDT

For growth investors, PAVmed Inc.

(PAVM) is the stronger pick with 22. 1% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). PAVmed Inc. (PAVM) offers the better valuation at 14. 4x trailing P/E, making it the more compelling value choice. Analysts rate PAVmed Inc. (PAVM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PAVmed Inc.

(PAVM) is the cheapest at 14. 4x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus PAVM's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PAVmed Inc.

(PAVM) is pulling ahead at 22. 1% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: PAVmed Inc. grew EPS 105. 4% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, PAVM leads at 81. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PAVmed Inc.

(PAVM) is the more profitable company, earning 1329% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 1329% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -1485. 4% for PAVM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, MDT (3.

6% yield), SYK (1. 1% yield) pay a dividend. PAVM, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAVM is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. SYK, MDT pay a dividend while PAVM, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.